Building B
5th Floor No. 699 Zhong Ke Road Pudong New District
Shanghai
China
86 21 5078 3699
https://www.jwtherapeutics.com
版塊: Healthcare
行業: Biotechnology
全職員工: 398
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Dr. Yiping Li M.D. | Co-founder, Executive Chairman of the Board & CEO | 6.23M | 無 | 1964 |
Cao Xiaoping Ph.D. | Senior Vice President of Tech Operations | 無 | 無 | 無 |
Dr. Shaun Paul Cordoba Ph.D. | Senior VP & Chief Scientific Officer | 無 | 無 | 1980 |
Mr. Raymond J. Hage Jr. | Senior Vice President of Corporate Development | 無 | 無 | 1968 |
Mr. Qiong Wu | Senior VP & Chief Commercial Officer | 無 | 無 | 1974 |
Mr. Mark J. Gilbert M.D. | Senior Advisor & Acting Chief Medical Officer | 無 | 無 | 無 |
Ms. Ka Man Ng A.C.I.S., A.C.S. | Company Secretary | 無 | 無 | 1978 |
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People's Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
截至 無 止,藥明巨諾-B 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。